A phase 3 trial evaluates the efficacy of mezigdomide plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in ...
LONDON, UK / ACCESS Newswire / June 26, 2026 / Guardian Metal Resources plc (NYSE.A:GMTL)(LON:GMET)(OTCQB:GMTLF), a strategic ...
After a four-month investigation, Nature Medicine has decided to pull a viral study that linked early-day PD-1/chemo ...
SEQUOIA subgroup shows zanubrutinib sustains 64% PFS at 6 years in CLL patients ≥80, with low early discontinuations and ...
Post hoc analysis of the MajesTEC-3 trial shows the efficacy of the teclistamab plus daratumumab combination in hard-to-treat ...
The Swedish government has granted Leading Edge Materials (TSXV: LEM) a 25-year mining lease for what the company calls one ...
MedPage Today on MSN
Nature Retracts Cancer Study Linking Treatment Timing to Survival
Editors "no longer have confidence in the integrity of the results" ...
Today, Alliance Foundation Trials, LLC (AFT) was informed that the U.S. Food and Drug Administration has approved palbociclib ...
New data for Talvey and Tecvayli was presented at the annual meeting as J&J directs its therapies in earlier-line settings.
The game is on for TROP2 antibody-drug conjugates in first-line triple-negative breast cancer. | Less than a month after an approval for Daiichi Sankyo and AstraZeneca’s Datroway for front-line TNBC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results